Tirzepatide
SURMOUNT-CN
Eli Lilly · Phase 3 · Completed · Enrollment 210
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 10 Milligrams (mg) Tirzepatide | n/r | n/r | n/r | n/r |
| 15 mg Tirzepatide | 92.65% | 83.82% | 72.06% | n/r |
| Placebo | 29.41% | 14.71% | 2.94% | n/r |
| 10 mg Tirzepatide | 91.43% | 70% | 48.57% | n/r |
Not shown
- 10 Milligrams (mg) Tirzepatide: endpoint not reported